Open Orphan PLC - London-based pharmaceutical services - Subsidiary hVIVO is awarded new study with existing unnamed pharmacetical client to act as vaccination site for the client's respiratory syncytial virus vaccine candidate. hVIVO's specialist arm FluCamp will recruit 60 healthy volunteers to the new site clinic at Plumbers Row where trials will take place.
"This is a significant award for Open Orphan as it is our first study as a site...There are a great number of synergies between our core challenge study activities and new the site services, this will help us to conduct the new work in an efficient manner," says Chief Executive Officer Yamin Khan.
Current stock price: 14.05 pence, up 6.0% on Thursday
12-month change: down 59%
By Elizabeth Winter; elizabethwinter@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
